{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:27:52Z","timestamp":1790612872419,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1208\/s12249-020-01772-3","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T22:02:40Z","timestamp":1597356160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative Pharmacokinetics of Nimodipine in Rat Plasma and Tissues Following Intraocular, Intragastric, and Intravenous Administration"],"prefix":"10.1208","volume":"21","author":[{"given":"Fang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoyun","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manman","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"key":"1772_CR1","first-page":"518","volume":"44","author":"CC Lin","year":"2017","unstructured":"Lin CC, Xia ZH, Yang F. Various dosage forms of nimodipine: application and research advances. J Int Pharm Res. 2017;44:518\u201321.","journal-title":"J Int Pharm Res"},{"issue":"3","key":"1772_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s13318-015-0258-5","volume":"41","author":"J Koskim\u00e4ki","year":"2016","unstructured":"Koskim\u00e4ki J, Tarkia M, Ahtola-S\u00e4til\u00e4 T, Saloranta L, Laakso A, Frantz\u00e9n J. Absorption, elimination and cerebrospinal fluid concentrations of nimodipine in healthy beagle dogs receiving human intravenous and oral formulation. Eur J Drug Metab Pharmacokinet. 2016;41(3):295\u2013300.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"1772_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12028-019-00676-w","volume":"31","author":"M Kieninger","year":"2019","unstructured":"Kieninger M, Gruber M, Knott I, Dettmer K, Oefner PJ, Bele S, et al. Incidence of arterial hypotension in patients receiving peroral or continuous intra-arterial nimodipine after aneurysmal or perimesencephalic subarachnoid hemorrhage. Neurocrit Care. 2019;31(1):32\u20139.","journal-title":"Neurocrit Care"},{"issue":"8","key":"1772_CR4","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.04.024","volume":"28","author":"A Hajizadeh Barfejani","year":"2019","unstructured":"Hajizadeh Barfejani A, Rabinstein AA, Wijdicks EFM, Clark SL. Poor utilization of nimodipine in aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis. 2019;28(8):2155\u20138.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"1772_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10194-008-0074-2","volume":"9","author":"C Mj\u00e5set","year":"2008","unstructured":"Mj\u00e5set C, Russell MB. Intravenous nimodipine worsening prolonged attack of familial hemiplegic migraine. J Headache Pain. 2008;9:381\u20134.","journal-title":"J Headache Pain"},{"key":"1772_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jpba.2017.06.072","volume":"147","author":"M Jug","year":"2018","unstructured":"Jug M, Hafner A, Lovri\u0107 J, Kregar ML, Pepi\u0107 I, Vani\u0107 \u017d, et al. An overview of in vitro dissolution\/release methods for novel mucosal drug delivery systems. J Pharm Biomed Anal. 2018;147:350\u201366.","journal-title":"J Pharm Biomed Anal"},{"key":"1772_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40199-018-0209-1","volume":"26","author":"S Banerjee","year":"2018","unstructured":"Banerjee S, Kundu A. Lipid-drug conjugates: a potential nanocarrier system for oral drug delivery applications. Daru. 2018;26:65\u201375.","journal-title":"Daru."},{"key":"1772_CR8","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.3748\/wjg.v24.i47.5322","volume":"24","author":"E Antonelli","year":"2018","unstructured":"Antonelli E, Villanacci V, Bassotti G. Novel oral-targeted therapies for mucosal healing in ulcerative colitis. World J Gastroenterol. 2018;24:5322\u201330.","journal-title":"World J Gastroenterol"},{"key":"1772_CR9","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/jcph.1401","volume":"59","author":"PA Krieter","year":"2019","unstructured":"Krieter PA, Chiang CN, Gyaw S, McCann DJ. Comparison of the pharmacokinetic properties of naloxone following the use of FDA-approved intranasal and intramuscular devices versus a common improvised nasal naloxone device. J Clin Pharmacol. 2019;59:1078\u201384.","journal-title":"J Clin Pharmacol"},{"key":"1772_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.lfs.2019.04.014","volume":"226","author":"M Nasr","year":"2019","unstructured":"Nasr M, Wahdan SA. Neuroprotective effects of novel nanosystems simultaneously loaded with vinpocetine and piracetam after intranasal administration. Life Sci. 2019;226:117\u201329.","journal-title":"Life Sci"},{"key":"1772_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1208\/s12249-019-1439-3","volume":"20","author":"PR Ara\u00fajo","year":"2019","unstructured":"Ara\u00fajo PR, Calixto GMF, Silva IC, Paula Zago LH, Oshiro Junior JA, Pavan FR, et al. Mucoadhesive in situ gelling liquid crystalline precursor system to improve the vaginal administration of drugs. AAPS Pharm Sci Tech. 2019;20:225.","journal-title":"AAPS Pharm Sci Tech"},{"key":"1772_CR12","first-page":"1969","volume":"33","author":"YY Cheng","year":"2013","unstructured":"Cheng YY. Progress in the application of rectal preparations. China J Hosp Pharm. 2013;33:1969\u201371.","journal-title":"China J Hosp Pharm"},{"key":"1772_CR13","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ijpharm.2014.02.030","volume":"465","author":"SS Razavi Rohani","year":"2014","unstructured":"Razavi Rohani SS, Abnous K, Tafaghodi M. Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients. Int J Pharm. 2014;465:464\u201378.","journal-title":"Int J Pharm"},{"key":"1772_CR14","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1080\/03639045.2019.1583758","volume":"45","author":"N Marasini","year":"2019","unstructured":"Marasini N, Kaminskas LM. Subunit-based mucosal vaccine delivery systems for pulmonary delivery\u2014are they feasible? Drug Dev Ind Pharm. 2019;45:882\u201394.","journal-title":"Drug Dev Ind Pharm"},{"key":"1772_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijpharm.2019.05.059","volume":"566","author":"M Tighsazzadeh","year":"2019","unstructured":"Tighsazzadeh M, Mitchell JC, Boateng JS. Development and evaluation of performance characteristics of timolol-loaded composite ocular films as potential delivery platforms for treatment of glaucoma. Int J Pharm. 2019;566:111\u201325.","journal-title":"Int J Pharm"},{"key":"1772_CR16","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1124\/jpet.118.248427","volume":"336","author":"BC Askew","year":"2018","unstructured":"Askew BC, Furuya T, Edwards DS. Ocular distribution and pharmacodynamics of SF0166, a topically administered integrin antagonist, for the treatment of retinal diseases. J Pharmacol Exp Ther. 2018;336:244\u201350.","journal-title":"J Pharmacol Exp Ther"},{"key":"1772_CR17","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.addr.2006.07.024","volume":"58","author":"E Mannermaa","year":"2006","unstructured":"Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev. 2006;58:1136\u201363.","journal-title":"Adv Drug Deliv Rev"},{"key":"1772_CR18","first-page":"3021","volume":"32","author":"DJ Pillion","year":"1991","unstructured":"Pillion DJ, Bartlett JD, Meezan E, Yang M, Crain RJ, Grizzle WE. Systemic absorption of insulin delivered topically to the rat eye. Invest Ophthalmol Vis Sci. 1991;32:3021\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1772_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ejpb.2005.01.009","volume":"60","author":"M Hornof","year":"2005","unstructured":"Hornof M, Toropainen E, Urtti A. Cell culture models of the ocular barriers. Eur J Pharm Biopharm. 2005;60:207\u201325.","journal-title":"Eur J Pharm Biopharm"},{"key":"1772_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ijbiomac.2015.12.077","volume":"85","author":"MS Baig","year":"2016","unstructured":"Baig MS, Ahad A, Aslam M, Imam SS, Aqil M, Ali A. Application of box-Behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery: optimization, in vitro release, ocular tolerance, and antibacterial activity. Int J Biol Macromol. 2016;85:258\u201370.","journal-title":"Int J Biol Macromol"},{"key":"1772_CR21","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3797\/scipharm.1001-06","volume":"78","author":"S Gupta","year":"2010","unstructured":"Gupta S, Vyas SP. Carbopol\/chitosan based pH triggered in situ gelling system for ocular delivery of timolol maleate. Sci Pharm. 2010;78:959\u201376.","journal-title":"Sci Pharm"},{"key":"1772_CR22","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1517\/17425247.2013.796360","volume":"10","author":"H Almeida","year":"2013","unstructured":"Almeida H, Amaral MH, Lob\u00e3o P, Sousa Lobo JM. Applications of poloxamers in ophthalmic pharmaceutical formulations: an overview. Expert Opin Drug Deliv. 2013;10:1223\u201337.","journal-title":"Expert Opin Drug Deliv"},{"key":"1772_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/jop.1993.9.85","volume":"9","author":"GC Chiou","year":"1993","unstructured":"Chiou GC, Li BH. Chronic systemic delivery of insulin through the ocular route. J Ocul Pharmacol. 1993;9:85\u201390.","journal-title":"J Ocul Pharmacol"},{"key":"1772_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1089\/jop.1991.7.351","volume":"7","author":"GC Chiou","year":"1991","unstructured":"Chiou GC, Shen ZF, Zheng YQ. Systemic absorption of oxytocin and vasopressin through eyes in rabbits. J Ocul Pharmacol. 1991;7:351\u20139.","journal-title":"J Ocul Pharmacol"},{"key":"1772_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.17219\/pim\/102978","volume":"48","author":"M Kara\u017aniewicz-\u0141ada","year":"2018","unstructured":"Kara\u017aniewicz-\u0141ada M, B\u0105ba K, Dolatowski F, Dobrowolska A, Rakicka M. The polymorphism of statins and its effect on their physicochemical properties. Polim Med. 2018;48:77\u201382.","journal-title":"Polim Med"},{"key":"1772_CR26","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.apsb.2015.03.011","volume":"5","author":"R Zhang","year":"2015","unstructured":"Zhang R, Mao P, Zhang T, Ma C, Jin B, Li T. Pharmacokinetic analysis and tissue distribution of Vam3 in the rat by a validated LC-MS\/MS method. Acta Pharm Sin B. 2015;5:254\u201363.","journal-title":"Acta Pharm Sin B"},{"key":"1772_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.fitote.2013.06.012","volume":"90","author":"Q Li","year":"2013","unstructured":"Li Q, Zhu Q, Zhang X, Hua C, Deng X, Zhao T, et al. A liquid chromatography-tandem mass spectrometry method for pharmacokinetics and tissue distribution of a camptothecin quaternary derivative in rats. Fitoterapia. 2013;90:57\u201364.","journal-title":"Fitoterapia."},{"issue":"6","key":"1772_CR28","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0039-6257(01)00211-9","volume":"45","author":"KR Wilhelmus","year":"2001","unstructured":"Wilhelmus KR. The Draize eye test. Surv Ophthalmol. 2001;45(6):493\u2013515.","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"1772_CR29","first-page":"123","volume":"33","author":"T Luechtefeld","year":"2016","unstructured":"Luechtefeld T, Maertens A, Russo DP, Rovida C, Zhu H, Hartung T. Analysis of Draize eye irritation testing and its prediction by mining publicly available 2008-2014 REACH data. ALTEX. 2016;33(2):123\u201334.","journal-title":"ALTEX."},{"key":"1772_CR30","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1211\/jpp.58.11.0002","volume":"58","author":"J Yu","year":"2006","unstructured":"Yu J, He HB, Tang X. Formulation and evaluation of nimodipine-loaded lipid microspheres. J Pharm Pharmacol. 2006;58:1429\u201335.","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"1772_CR31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12272-015-0685-5","volume":"39","author":"J Li","year":"2016","unstructured":"Li J, Fu Q, Liu X, Li M, Wang Y. Formulation of nimodipine nanocrystals for oral administration. Arch Pharm Res. 2016;39(2):202\u201312.","journal-title":"Arch Pharm Res"},{"key":"1772_CR32","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2165\/00003495-198937050-00004","volume":"37","author":"MS Langley","year":"1898","unstructured":"Langley MS, Sorkin EM. Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs. 1898;37:669\u201399.","journal-title":"Drugs."},{"key":"1772_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2147\/IJN.S186899","volume":"14","author":"Z Teng","year":"2019","unstructured":"Teng Z, Yu M, Ding Y, Zhang H, Shen Y, Jiang M, et al. Preparation and characterization of nimodipine-loaded nanostructured lipid systems for enhanced solubility and bioavailability. Int J Nanomedicine. 2019;14:119\u201333.","journal-title":"Int J Nanomedicine"},{"issue":"4","key":"1772_CR34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/13543784.2018.1460353","volume":"27","author":"RT Tallarico","year":"2018","unstructured":"Tallarico RT, Pizzi MA, Freeman WD. Investigational drugs for vasospasm after subarachnoid hemorrhage. Expert Opin Investig Drugs. 2018;27(4):313\u201324.","journal-title":"Expert Opin Investig Drugs"},{"key":"1772_CR35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-3-319-04981-6_47","volume":"120","author":"N Etminan","year":"2015","unstructured":"Etminan N, Macdonald RL, Davis C, Burton K, Steiger HJ, H\u00e4nggi D. Intrathecal application of the nimodipine slow-release microparticle system eg-1962 for prevention of delayed cerebral ischemia and improvement of outcome after aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl. 2015;120:281\u20136.","journal-title":"Acta Neurochir Suppl"},{"key":"1772_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1089\/jop.1994.10.93","volume":"10","author":"GC Chiou","year":"1994","unstructured":"Chiou GC. Systemic delivery of polypeptide drugs through ocular route. J Ocul Pharmacol. 1994;10:93\u20139.","journal-title":"J Ocul Pharmacol"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-020-01772-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-020-01772-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-020-01772-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T18:58:08Z","timestamp":1696532288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-020-01772-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["1772"],"URL":"https:\/\/doi.org\/10.1208\/s12249-020-01772-3","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"14 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"234"}}